Difference between revisions of "Stephen Moses"

From IntactiWiki
Jump to navigation Jump to search
m (wikify 'uncircumcised')
m (wikify HIV)
Line 55: Line 55:
 
  |DOI=10.1111/j.1464-410X.2005.05810.x
 
  |DOI=10.1111/j.1464-410X.2005.05810.x
 
  |accessdate=
 
  |accessdate=
}}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an HIV prevention method.<ref>{{REFweb
+
}}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an [[HIV]] prevention method.<ref>{{REFweb
 
  |last=World Health Organization
 
  |last=World Health Organization
 
  |first=
 
  |first=
Line 65: Line 65:
  
 
== Interests ==
 
== Interests ==
According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/HIV transmission.<ref name='moses-bio'>{{REFweb
+
According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/[[HIV]] transmission.<ref name='moses-bio'>{{REFweb
 
  |last=Moses
 
  |last=Moses
 
  |first=Stephen
 
  |first=Stephen
Line 85: Line 85:
 
  |url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/
 
  |url=https://www.doctorsopposingcircumcision.org/for-professionals/alleged-medical-benefits/hivaids/
 
  |accessdate=2020-03-23
 
  |accessdate=2020-03-23
}}</ref>Of the three {{#tip-text:RCT|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as HIV prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.
+
}}</ref>Of the three {{#tip-text:RCT|Randomized controlled trial}}s being used by the [[WHO]] to endorse circumcision as [[HIV]] prevention, Stephen Moses and [[Robert C. Bailey]] headed the {{#tip-text:RCT|Randomized controlled trial}} that was carried out in Kenya.<ref>Bailey RC, Moses S, Parker CB, et al. Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial. ''Lancet'' 2007;369:643-56. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60312-2/abstract Abstract]</ref> Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.
  
Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in HIV was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much HIV infection as intact men.<ref>{{REFjournal
+
Moses' research on circumcision protection from [[HIV]] infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent ''relative'' reduction in [[HIV]] was claimed, the ''absolute'' reduction was a statistically insignificant 1.3 percent.<ref name="boyle-hill2011">{{BoyleGJ HillG 2011}}</ref> Garenne & Matthews (2019) report that circumcised men have as much [[HIV]] infection as intact men.<ref>{{REFjournal
 
  |last=Garenne
 
  |last=Garenne
 
  |init=M
 
  |init=M
Line 113: Line 113:
  
 
== Active projects ==
 
== Active projects ==
* A randomized, controlled trial of male circumcision to reduce HIV incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
+
* A randomized, controlled trial of male circumcision to reduce [[HIV]] incidence in Kisumu, Kenya.<ref name='moses-bio'/><br><small>[[National Institutes of Health]].</small>
* Scaling up HIV prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
+
* Scaling up [[HIV]] prevention in Karnataka and southern Maharashtra, Phase II.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Monitoring and evaluation of the Avahan project in India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
 
* Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.<ref name='moses-bio'/><br><small>[[Bill & Melinda Gates Foundation]].</small>
* Mapping key populations for HIV prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>
+
* Mapping key populations for [[HIV]] prevention in Sri Lanka.<ref name='moses-bio'/><br><small>World Bank.</small>
  
 
== Recent publications ==
 
== Recent publications ==
Line 140: Line 140:
 
  |accessdate=
 
  |accessdate=
 
}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small>
 
}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small>
* Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.<ref>{{REFjournal
+
* Top Achievements in Health Research: Male circumcision: a new approach to reducing [[HIV]] transmission.<ref>{{REFjournal
 
  |last=Moses
 
  |last=Moses
 
  |init=S
 
  |init=S
Line 156: Line 156:
 
  |accessdate=
 
  |accessdate=
 
}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small>
 
}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small>
* Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal
+
* Does sex in the early period after circumcision increase [[HIV]]-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal
 
  |last=Mehta
 
  |last=Mehta
 
  |init=SD
 
  |init=SD
Line 177: Line 177:
 
}}
 
}}
 
</ref><br><small>Mehta SD, '''[[Ronald Gray|Gray RH]]''', '''[[Bertran Auvert|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer|Wawer MJ]]''', '''[[Robert C. Bailey|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small>
 
</ref><br><small>Mehta SD, '''[[Ronald Gray|Gray RH]]''', '''[[Bertran Auvert|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer|Wawer MJ]]''', '''[[Robert C. Bailey|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small>
* Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.<ref>{{REFjournal
+
* Male circumcision for [[HIV]] prevention in young men in Kisumu, Kenya: a randomised controlled trial.<ref>{{REFjournal
 
  |last=Bailey
 
  |last=Bailey
 
  |init=RC
 
  |init=RC
Line 198: Line 198:
 
}}
 
}}
 
</ref><br><small>'''[[Robert C. Bailey|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small>
 
</ref><br><small>'''[[Robert C. Bailey|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small>
* Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa.<ref>{{REFjournal
+
* Modelling the public health impact of male circumcision for [[HIV]] prevention in high prevalence areas in Africa.<ref>{{REFjournal
 
  |last=Nagelkerke
 
  |last=Nagelkerke
 
  |init=NJ
 
  |init=NJ

Revision as of 16:39, 24 November 2021

Stephen Moses.jpg
Stephen Moses
Associates With:
Gilgal Society
Circlist
Colleagues & Benefactors:
Daniel T. Halperin
Edgar J. Schoen
Robert C. Bailey
Bertran Auvert
Maria J. Wawer
Brian J. Morris
Avahan project
Funded by The World Bank

Stephen Moses, Professor, Departments of Medical Microbiology, Community Health Sciences and Medicine. Stephen Moses has been a circumcision proponent since at least 1994.[1] Moses (along with Robert C. Bailey) was responsible for one of the three major African circumcision trials (funded by NIAID and the Canadian Institutes of Health Research)[2] which are being used by the World Health Organization (under the guide of UNAIDS) to endorse circumcision as an HIV prevention method.[3]

Interests

According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/HIV transmission.[4] Moses has been an advocate of circumcision since at least 1994.[1]

RCT in Kenya

Three trials were funded by the American National Institutes of Health.[5]Of the three RCTs being used by the WHO to endorse circumcision as HIV prevention, Stephen Moses and Robert C. Bailey headed the RCT that was carried out in Kenya.[6] Moses obviously brought his pre-existing bias in favor of male circumcision into the trial, so he did not start from a neutral position.

Moses' research on circumcision protection from HIV infection is now completely discredited. Boyle & Hill (2011) reviewed the three randomized controlled trials (RCTs) and found disabling methodological and statistical errors in all three. Although a 60 percent relative reduction in HIV was claimed, the absolute reduction was a statistically insignificant 1.3 percent.[7] Garenne & Matthews (2019) report that circumcised men have as much HIV infection as intact men.[8]

Active projects

Recent publications

  • Prevalence and risk factors for human papillomavirus infection by penile site in uncircumcised Kenyan men.[9]
    Smith JS, Hudgens MG, Bailey RC, Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.
  • Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.[10]
    Moses S. CIHR/CMAJ 2009; 181: E134-5.
  • Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.[11]
    Mehta SD, Gray RH, Auvert B, Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, Wawer MJ, Bailey RC. AIDS 2009; 23: 1557-64.
  • Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.[12]
    Bailey RC, Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.
  • Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa.[13]
    Nagelkerke NJD, Moses S, de Vlas S, Bailey RC. BMC Infect Dis 2007; 7: 16.
  • Adult male circumcision outcomes: experience in a developing country setting.[14]
    Krieger J, Bailey RC, Agot K, Parker C, Ndinya-Achola JO, Moses S, et al. Urol Int 2007; 78: 235-40.

See also

References

  1. a b REFjournal Moses S, Plummer FA, Bradley JE, Ndinya-Achola JO, Nagelkerke NJ, Ronald AR. The association between lack of male circumcision and risk for HIV infection: a review of the epidemiological data. Sex Transm Dis. 1994; 21: 201-210.
  2. REFjournal Krieger JN, Bailey RC, Opeya J, et al. Adult male circumcision: results of a standardized procedure in Kisumu District, Kenya. BJU Int.. November 2005; 96(7): 1109–13. PMID. DOI.
  3. REFweb World Health Organization (27 March 2007). WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention. Retrieved 23 February 2011.
  4. a b c d e f REFweb Moses, Stephen. Dr. Stephen Moses, University of Manitoba. Retrieved 23 February 2011.
  5. REFweb (2016). HIV/AIDS, Doctors Opposing Circumcision. Retrieved 23 March 2020.
    Quote: ...funding from the United States National Institutes of Health to conduct randomized controlled trials (RCTs) in Africa.
  6. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56. Abstract
  7. REFjournal Boyle GJ, Hill G. Sub-Saharan African randomised clinical trials into male circumcision and HIV transmission: Methodological, ethical and legal concerns PDF. Thompson Reuter. December 2011; 19(2): 316-34. PMID. Retrieved 30 December 2020.
  8. REFjournal Garenne M, Matthews A. Voluntary medical male circumcision and HIV in Zambia: expectations and observations. J Biosoc Science. 1 October 2019; 14: 1-13. PMID. DOI. Retrieved 25 March 2020.
  9. REFjournal Smith JS, Backes DM, Hudgens MG, et al. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int. J. Cancer. January 2010; 126(2): 572–7. PMID. PMC. DOI.
  10. REFjournal Moses S. Male circumcision: a new approach to reducing HIV transmission. CMAJ. October 2009; 181(8): E134–5. PMID. PMC. DOI.
  11. REFjournal Mehta SD, Gray RH, Auvert B, et al. Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials. AIDS. July 2007; 23(12): 1557–64. PMID. PMC. DOI.
  12. REFjournal Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. February 2007; 369(9562): 643–56. PMID. DOI.
  13. REFjournal Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect. Dis.. 2007; 7: 16. PMID. PMC. DOI.
  14. REFjournal Krieger JN, Bailey RC, Opeya JC, et al. Adult male circumcision outcomes: experience in a developing country setting. Urol. Int.. 2007; 78(3): 235–40. PMID. DOI.